hotspot -WSS

hotspot

author：knowledge 2025-09-29 22:52:18 - browse：3

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The creative science of coining drug names

WSS

Welsh Carson private equity firm escapes from FTC antitrust case

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

leisure time

hotspot

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Crowdfunding for medical bills sidesteps core problem, author says

Medical leaders decry Supreme Court decision on affirmative action

Chemotherapy before breast cancer surgery might fuel metastasis

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Sports medicine is finally prioritizing gender equality

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Guidelines to prevent youth baseball injuries need more muscle

Is it ever OK for doctors to lie to their patients?

explore

AltruBio raises $225 million to develop ulcerative colitis drug

Oprah kicked off a national conversation on obesity. Let's have it

Primary care doctor shortage won't be solved by free med school tuition

Supreme Court mifepristone arguments center on docs' right to sue

Decaf coffee targeted by food safety group under obscure FDA rule

Brain technologies pose threats that are all too real, experts warn

leisure time

hotspot

focus

leisure time